'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Clicks: 487
ID: 55200
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 10 articles by views in Nature Immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract is not available for this article.
Login to Search Abstract
Reference Key
mastellos2019stealthnature Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mastellos, Dimitrios C;Blom, Anna M;Connolly, E Sander;Daha, Mohamed R;Geisbrecht, Brian V;Ghebrehiwet, Berhane;Gros, Piet;Hajishengallis, George;Holers, V Michael;Huber-Lang, Markus;Kinoshita, Taroh;Mollnes, Tom E;Montgomery, Robert A;Morgan, B Paul;Nilsson, Bo;Pio, Ruben;Ricklin, Daniel;Risitano, Antonio M;Taylor, Ronald P;Mantovani, Alberto;Ioannidis, John P A;Lambris, John D;
Journal Nature Immunology
Year 2019
DOI
10.1038/s41590-019-0503-1
URL
Keywords
Docking Cancer Cytotoxicity doxorubicin admet cdk7

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.